Scotiabank lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $41 and keeps a Sector Perform rating on the shares. The firm cut its price target on the stock based on the lower probability of success for its Phase 1 trial of JANX007, which the firm believes is “more appropriate” for a Phase 1 cancer drug with limited patient exposure, the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc
- Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position
- Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007
- Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback
- Janux Therapeutics reports Q1 EPS (38c), consensus (39c)